---
title: "Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Alpha-emitting radiopharmaceuticals"
description: "Formulary evidence on Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Alpha-emitting radiopharmaceuticals. Topics: FDA-approved indication and dosing, Symptomatic bone-metastatic disease: trial population, Symptomatic bone-metastatic disease: overall survival versus placebo, Symptomatic skeletal events, and 4 further topics. 8 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description/alpha-emitting-radiopharmaceuticals"
published: "2026-11-15T21:45:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Alpha-emitting radiopharmaceuticals

<a id="heading-2.2.2.1.6"></a>

## 2.2.2.1.6 Alpha-emitting Radiopharmaceuticals

<a id="topic-2.2.2.1.6-1"></a>

### FDA-approved indication and dosing

> “Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.”
> “The dose regimen of Xofigo is 55 kBq (1.49 microcurie) per kg body weight, given at 4 week intervals for 6 injections.”

Source: [Xofigo prescribing information (2019)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203971s016lbl.pdf)

<a id="topic-2.2.2.1.6-2"></a>

### Symptomatic bone-metastatic disease: trial population

> “Patients with visceral metastases and malignant lymphadenopathy exceeding 3 cm were excluded.”
> “Prior bisphosphonates were used by 41% of patients and 58% had received prior docetaxel.”

Source: [Xofigo prescribing information (2019)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203971s016lbl.pdf)

<a id="topic-2.2.2.1.6-3"></a>

### Symptomatic bone-metastatic disease: overall survival versus placebo

| Analysis | Radium Ra 223 dichloride, median months (95% CI) | Placebo, median months (95% CI) | Hazard ratio (95% CI) |
| --- | --- | --- | --- |
| Interim analysis | “14.0 (12.1, 15.8)” | “11.2 (9.0, 13.2)” | “0.695 (0.552, 0.875)” |
| Updated analysis | “14.9 (13.9, 16.1)” | “11.3 (10.4, 12.8)” | “0.695 (0.581, 0.832)” |

Source: [Xofigo prescribing information (2019)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203971s016lbl.pdf)

<a id="topic-2.2.2.1.6-4"></a>

### Symptomatic skeletal events

> “The rates of symptomatic skeletal events (33% vs. 38%) and spinal cord compression (4% vs. 7%) were also statistically significantly improved.”

Source: [National Cancer Institute Prostate Cancer Treatment PDQ](https://www.cancer.gov/types/prostate/hp/prostate-treatment-pdq)

<a id="topic-2.2.2.1.6-5"></a>

### Bone marrow suppression

> “In the randomized trial, 2% of patients on the Xofigo arm experienced bone marrow failure or ongoing pancytopenia compared to no patients treated with placebo.”
> “Outside of a clinical trial, concomitant use with chemotherapy is not recommended due to the potential for additive myelosuppression.”

Source: [Xofigo prescribing information (2019)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203971s016lbl.pdf)

<a id="topic-2.2.2.1.6-6"></a>

### Combination with abiraterone acetate

> “Xofigo is not recommended for use in combination with abiraterone acetate plus prednisone/prednisolone outside of clinical trials.”
> “At the primary analysis, an increased incidence of fractures (28.6% vs 11.4%) and deaths (38.5% vs 35.5%) have been observed in patients who received Xofigo in combination with abiraterone acetate plus prednisone/prednisolone compared to patients who received placebo in combination with abiraterone acetate plus prednisone/prednisolone.”

Source: [Xofigo prescribing information (2019)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203971s016lbl.pdf)

<a id="topic-2.2.2.1.6-7"></a>

### Combination with enzalutamide

> “Radiographic PFS was 16.4 (95% CI 13.8-19.2) months in the ENZ arm and 19.4 (95% CI 17.1-25.3) months in the ENZ-RAD arm.”
> “The HR for OS was 0.69 (95% CI 0.52-0.90; p = 0.0031), with median OS in the preplanned interim analysis of 35.0 (95% CI 28.8-38.9) months in the ENZ arm and 42.3 (95% CI 36.8-49.1) months in the ENZ-RAD arm.”
> “After an amendment, co-administration of zoledronic acid or denosumab (bone protecting agents) was obligatory.”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

<a id="topic-2.2.2.1.6-8"></a>

### Guideline recommendations

> “Offer enzalutamide plus radium-223 to asymptomatic or mildly symptomatic mCRPC patients with bone metastases without visceral metastases.”
> “Due to safety concerns following ARPI combination treatment use of radium-223 was restricted by EMA to after docetaxel and at least one AR targeted agent”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

Additional sources: [Parker et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23863050/)

## Related pages
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Terms and abbreviations](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations.md)
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product information and disease description](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical evidence](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic information and modeling report](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: References](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references.md)
